Abcuro, Inc., a late-stage clinical biotechnology company developing potentially first-in-class immunotherapies designed to ...

But the biotech’s newest update has failed to garner the same investor enthusiasm, with the company’s stock nearly halved following the data drop.

CLN-049 monotherapy demonstrates promising efficacy, including multiple complete responses and encouraging response durability, in a heavily pretreated all-comer population of patients with R/R AML 31 ...

The global incidence of basal cell carcinoma is increasing due to prolonged exposure to ultraviolet (UV) radiation, genetic predispositions, and an aging population that is more susceptible to skin ...

Although policies can help create structure, they don’t build consistent digital habits—those have to be taught, modeled, ...

Poster presentation highlights promising results from Phase 1b/2 TENACITY-01 study of CTD402 in T-Cell and myeloid leukemiasFindings underscore ...

The 2025 meeting of the American Society of Hematology features some of the newest developments in blood cancers and rare ...

Perettie’s confidence stems from data shared at ASH on Dec. 6, when Kite revealed that patients treated with the Arcellx-partnered autologous therapy achieved a 96% overall response rate at the 15.9 ...

Results from the Phase 1/2 Trial are a Foundation for the Ongoing Pivotal Study of Soficabtagene Geleucel for R/R T-Cell ALL/ ...

The release of Phase III Stage 1 data for gotistobart (BNT316/ONC-392) at NACLC 2025 marks one of the most significant ...

XmAb819 demonstrated a manageable safety profile with primarily grade 1 or 2 cytokine release syndrome and no neurotoxicity in ccRCC patients. The trial involved 69 patients, with a 25% objective ...

Imviva Biotech, a clinical-stage biotechnology company developing next-generation allogeneic CAR-T cell therapies, today presented clinical data for CTD402, its investigational allogeneic anti-CD7 CAR ...